Long noncoding RNA AI662270 promotes kidney fibrosis through enhancing METTL3 ‐mediated m 6 A modification of CTGF mRNA
The FASEB Journal · 2023
DOI: 10.1096/fj.202202012rrr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Yanyan Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, P.R. China. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, RNA, Long Noncoding. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), National Natural Science Foundation of China.
Abstract (Originalsprache)
The sustained release of profibrotic cytokines, mainly transforming growth factor‐β (TGF‐β), leads to the occurrence of kidney fibrosis and chronic kidney disease (CKD). Connective tissue growth factor (CTGF) appears to be an alternative target to TGF‐β for antifibrotic therapy in CKD. In this study, we found that long noncoding RNA AI662270 was significantly increased in various renal fibrosis models. In vivo, ectopic expression of AI662270 alone was sufficient to activate interstitial fibroblasts and drive kidney fibrosis, whereas inhibition of AI662270 blocked the activation of interstitial fibroblasts and ameliorated kidney fibrosis in various murine models. Mechanistic studies revealed that overexpression of AI662270 significantly increased CTGF product, which was required for the role of AI662270 in driving kidney fibrosis. Furthermore, AI662270 binds to the CTGF promoter and directly interacts with METTL3, the methyltransferase of RNA N 6 ‐methyladenosine (m 6 A) modification. Functionally, AI662270‐mediated recruitment of METTL3 increased the m 6 A methylation of CTGF mRNA and consequently enhanced CTGF mRNA stability. In conclusion, our results support that AI662270 promotes CTGF expression at the posttranscriptional stage by recruiting METTL3 to the CTGF promoter and depositing m 6 A modifications on the nascent mRNA, thereby, uncovering a novel regulatory mechanism of CTGF in the pathogenesis of kidney fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, P.R. China.
- State Key Laboratory of Analytical Chemistry for Life Sciences and Collaborative Innovation Center of Chemistry for Life Sciences, Nanjing University, Nanjing, P.R. China.
ORCID-Profile: Zhi Ding, Lei Dong, Jiangning Chen, Yuhui Zang
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- National Natural Science Foundation of China
Zitieren
APA
Sun, Y., Ge, J., Shao, F., Ren, Z., Huang, Z., Ding, Z., Dong, L., Chen, J., Zhang, J., & Zang, Y. (2023). Long noncoding RNA AI662270 promotes kidney fibrosis through enhancing METTL3 ‐mediated m 6 A modification of CTGF mRNA. The FASEB Journal. https://doi.org/10.1096/fj.202202012rrr
Vancouver
Sun Y, Ge J, Shao F, Ren Z, Huang Z, Ding Z, et al. Long noncoding RNA AI662270 promotes kidney fibrosis through enhancing METTL3 ‐mediated m 6 A modification of CTGF mRNA. The FASEB Journal. 2023. doi:10.1096/fj.202202012rrr
BibTeX
@article{Sun2023,
author = {Sun, Yanyan and Ge, Jia and Shao, Fang and Ren, Zhengrong and Huang, Zhen and Ding, Zhi and Dong, Lei and Chen, Jiangning and Zhang, Junfeng and Zang, Yuhui},
title = {Long noncoding RNA AI662270 promotes kidney fibrosis through enhancing METTL3 ‐mediated m 6 A modification of CTGF mRNA},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202202012rrr}
}
EUVIMED